<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783430</url>
  </required_header>
  <id_info>
    <org_study_id>2014_22</org_study_id>
    <secondary_id>2014-004361-24</secondary_id>
    <secondary_id>PHRCI_2013</secondary_id>
    <nct_id>NCT02783430</nct_id>
  </id_info>
  <brief_title>Evaluation of the Initial Prescription of Ketamine and Milnacipran for Depression in Palliative Care</brief_title>
  <acronym>KETAPAL</acronym>
  <official_title>Evaluation of the Initial Prescription of Ketamine and Milnacipran for Depression in Palliative Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      KetaPal is a placebo-controlled randomized trial designed to demonstrate the antidepressant
      action of ketamine in palliative care situations. Half of participants will receive Ketamine
      and Milnacipran in combination, while the other half will receive a Placebo and Milnacipran
      in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketamine, a molecule mainly used as an analgesic in palliative care, turns out to be an
      excellent fast acting antidepressant. By acting as an NMDA receptor antagonist, its mechanism
      of action is complementary to classical and long acting antidepressants like Selective
      Serotonin Reuptake Inhibitors (SSRI). In particular, ketamine is able to boost synaptogenesis
      in only a few hours whereas long-term prescription of SSRI can stimulate neurogenesis.

      The purpose of this study is to evaluate a new therapeutic strategy that could integrate
      ketamine in the same time than SSRI, to control depression symptoms faster and optimize
      patient's quality of life complementary to treatments of cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS Score</measure>
    <time_frame>At day 1, At day 2</time_frame>
    <description>Measure of the change of Depression Intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EUROHIS-QOL 8</measure>
    <time_frame>at day 0, at day 15</time_frame>
    <description>Measure of the improvement of quality of life after 15 days of treatment. EUROHIS-QOL 8-item index, a shortened version of the World Health Organization Quality of Life Instrument-Abbreviated Version (WHOQOL-BREF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of request of early death (suicidal intentions or euthanasia or physician-assisted suicide)</measure>
    <time_frame>at day 0, at day 1, at day 2, at day 4, at day 8, at day 15</time_frame>
    <description>measure request of suicidal intentions made by the patient on explicit request of the clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression scale (HAD)</measure>
    <time_frame>at day 0, at day 1, at day 2, at day 4, at day 8, at day 15</time_frame>
    <description>The items of the scale limit confounding factors related to physical comorbidity . The answers are simple and quick . It is a wide choice and recommended for depression studies in palliative care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS Score</measure>
    <time_frame>at day 0, at day 4, at day 8, at day 15</time_frame>
    <description>The MADRS scale quantifies the intensity of depressive symptoms, determine the number of responders (reduction in the initial score greater than or equal to 50%) and the number of patients in remission (score less than 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Score</measure>
    <time_frame>at day 0, at day 1, at day 2, at day 4, at day 8, at day 15</time_frame>
    <description>These hetero fast and well validated assessments help to complete the assessment by the clinician on the severity of the patient's situation and overall improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Scale Operation (EGF)</measure>
    <time_frame>at day 0, at day 15</time_frame>
    <description>Global Assessment of Functioning is a numerical scale ( from 0 to 100) used to evaluate the psychological, social and work of an individual .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edmonton Symptom Assessment System ( ESAS )</measure>
    <time_frame>at day 0, at day 1, at day 2, at day 4, at day 8, at day 15</time_frame>
    <description>Symptom Assessment Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Milnacipran + Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Milnacipran + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion</description>
    <arm_group_label>Milnacipran + Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)</description>
    <arm_group_label>Milnacipran + Ketamine</arm_group_label>
    <arm_group_label>Milnacipran + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One single perfusion during 40 minutes at the beginning of the inclusion</description>
    <arm_group_label>Milnacipran + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient

          -  Supported by a functional palliative care unit

          -  Having a severe and progressive disease diagnosed

          -  Meet the criteria for major depressive disorder as defined by DSM in its version 5

          -  MADRS &gt; 19 ( moderate to severe)

          -  No antidepressant treatment or treatment introduced for more than four weeks

          -  In ability to receive clear information and give consent

          -  Beneficiary of a social security scheme

        Exclusion Criteria:

          -  upper weight or equal to 100 kg

          -  ultimate phase (about 24 to 72 hours prior to death)

          -  unstable patient on cardiovascular diseases, including uncontrolled hypertension

          -  severe renal impairment (renal clearance less than 15 ml / min)

          -  psychiatric comorbidity: schizophrenia and schizoaffective disorder

          -  neurological comorbidity: recent cerebrovascular accident (Less than one month),
             Parkinson's disease, dementia

          -  treatment with ketamine received in the four weeks preceding the inclusion

          -  impaired judgment, cognitive or massive sensory impairment not allowing to receive
             clear information

          -  oral antidepressant treatment introduced less than four weeks ago

          -  dosage of oral antidepressant treatment upper than the marketing authorization for
             more than four weeks

          -  patient not covered by the social security system

          -  refusal to sign the consent

          -  minor patient or guardianship

          -  pregnant women (implementation of a urine pregnancy test before inclusion for women of
             childbearing age)

          -  lactating women

          -  intolerance or allergic reaction to ketamine or milnacipran.

          -  contraindications to the association of ketamine or milnacipran with the patient's
             usual treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine LEMAIRE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital of Valenciennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine LEMAIRE, MD</last_name>
    <email>lemaire-a@ch-valenciennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital,</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magali Pierrat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Magali Pierrat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoine Lemaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.afsos.org/Soins-palliatifs.html</url>
    <description>Organisation Mondiale de la Sante. Définition OMS soins palliatifs [Internet]. 2002 [cité 5 juin 2013]</description>
  </link>
  <link>
    <url>https://www.legifrance.gouv.fr/eli/decision/2004/12/20/SANH0424327S/jo</url>
    <description>Décision du 20 décembre 2004 relative à la vente au public de certaines spécialités pharmaceutiques et certains aliments diététiques destinés à des fins médicales spéciales par les pharmacies à usage intérieur</description>
  </link>
  <reference>
    <citation>Temel JS, Greer JA, Admane S, Gallagher ER, Jackson VA, Lynch TJ, Lennes IT, Dahlin CM, Pirl WF. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol. 2011 Jun 10;29(17):2319-26. doi: 10.1200/JCO.2010.32.4459. Epub 2011 May 9.</citation>
    <PMID>21555700</PMID>
  </reference>
  <reference>
    <citation>Lépine JP, Gasquet I, Kovess V, Arbabzadeh-Bouchez S, Nègre-Pagès L, Nachbaur G, Gaudin AF. [Prevalence and comorbidity of psychiatric disorders in the French general population]. Encephale. 2005 Mar-Apr;31(2):182-94. French.</citation>
    <PMID>15959445</PMID>
  </reference>
  <reference>
    <citation>Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011 Feb;12(2):160-74. doi: 10.1016/S1470-2045(11)70002-X. Epub 2011 Jan 19.</citation>
    <PMID>21251875</PMID>
  </reference>
  <reference>
    <citation>Atassi N, Cook A, Pineda CM, Yerramilli-Rao P, Pulley D, Cudkowicz M. Depression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011 Mar;12(2):109-12. doi: 10.3109/17482968.2010.536839. Epub 2010 Nov 24.</citation>
    <PMID>21091399</PMID>
  </reference>
  <reference>
    <citation>Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006 Oct 17;48(8):1527-37. Epub 2006 Sep 26.</citation>
    <PMID>17045884</PMID>
  </reference>
  <reference>
    <citation>Araujo SM, de Bruin VM, Daher Ede F, Almeida GH, Medeiros CA, de Bruin PF. Risk factors for depressive symptoms in a large population on chronic hemodialysis. Int Urol Nephrol. 2012 Aug;44(4):1229-35. doi: 10.1007/s11255-011-0032-9. Epub 2011 Jul 22.</citation>
    <PMID>21779919</PMID>
  </reference>
  <reference>
    <citation>Koenig HG, George LK, Peterson BL, Pieper CF. Depression in medically ill hospitalized older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry. 1997 Oct;154(10):1376-83.</citation>
    <PMID>9326819</PMID>
  </reference>
  <reference>
    <citation>Lloyd-Williams M, Friedman T, Rudd N. A survey of antidepressant prescribing in the terminally ill. Palliat Med. 1999 May;13(3):243-8.</citation>
    <PMID>10474711</PMID>
  </reference>
  <reference>
    <citation>Goldberg RJ, Mor V. A survey of psychotropic use in terminal cancer patients. Psychosomatics. 1985 Sep;26(9):745-8, 751.</citation>
    <PMID>4048377</PMID>
  </reference>
  <reference>
    <citation>Rumsfeld JS, Havranek E, Masoudi FA, Peterson ED, Jones P, Tooley JF, Krumholz HM, Spertus JA; Cardiovascular Outcomes Research Consortium. Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol. 2003 Nov 19;42(10):1811-7.</citation>
    <PMID>14642693</PMID>
  </reference>
  <reference>
    <citation>Cubo E, Bernard B, Leurgans S, Raman R. Cognitive and motor function in patients with Parkinson's disease with and without depression. Clin Neuropharmacol. 2000 Nov-Dec;23(6):331-4.</citation>
    <PMID>11575867</PMID>
  </reference>
  <reference>
    <citation>Lyketsos CG, Steele C, Baker L, Galik E, Kopunek S, Steinberg M, Warren A. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci. 1997 Fall;9(4):556-61.</citation>
    <PMID>9447496</PMID>
  </reference>
  <reference>
    <citation>Aimonino N, Tibaldi V, Barale S, Bardelli B, Pilon S, Marchetto C, Zanocchi M, Molaschi M. Depressive symptoms and quality of life in elderly patients with exacerbation of chronic obstructive pulmonary disease or cardiac heart failure: preliminary data of a randomized controlled trial. Arch Gerontol Geriatr. 2007;44 Suppl 1:7-12.</citation>
    <PMID>17317428</PMID>
  </reference>
  <reference>
    <citation>Newport DJ, Nemeroff CB. Assessment and treatment of depression in the cancer patient. J Psychosom Res. 1998 Sep;45(3):215-37. Review.</citation>
    <PMID>9776368</PMID>
  </reference>
  <reference>
    <citation>Rhondali W, Perceau E, Berthiller J, Saltel P, Trillet-Lenoir V, Tredan O, Coulon JP, Bruera E, Filbet M. Frequency of depression among oncology outpatients and association with other symptoms. Support Care Cancer. 2012 Nov;20(11):2795-802. doi: 10.1007/s00520-012-1401-3. Epub 2012 Feb 17.</citation>
    <PMID>22350596</PMID>
  </reference>
  <reference>
    <citation>Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry. 2006 Sep-Oct;28(5):396-402.</citation>
    <PMID>16950374</PMID>
  </reference>
  <reference>
    <citation>Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer. 2009 Nov 15;115(22):5349-61. doi: 10.1002/cncr.24561.</citation>
    <PMID>19753617</PMID>
  </reference>
  <reference>
    <citation>Lloyd-Williams M, Shiels C, Taylor F, Dennis M. Depression--an independent predictor of early death in patients with advanced cancer. J Affect Disord. 2009 Feb;113(1-2):127-32. doi: 10.1016/j.jad.2008.04.002. Epub 2008 Jun 16.</citation>
    <PMID>18558439</PMID>
  </reference>
  <reference>
    <citation>DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7.</citation>
    <PMID>10904452</PMID>
  </reference>
  <reference>
    <citation>Blank K, Robison J, Doherty E, Prigerson H, Duffy J, Schwartz HI. Life-sustaining treatment and assisted death choices in depressed older patients. J Am Geriatr Soc. 2001 Feb;49(2):153-61.</citation>
    <PMID>11207869</PMID>
  </reference>
  <reference>
    <citation>Rosenfeld KE, Wenger NS, Phillips RS, Connors AF, Dawson NV, Layde P, Califf RM, Liu H, Lynn J, Oye RK. Factors associated with change in resuscitation preference of seriously ill patients. The SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Arch Intern Med. 1996 Jul 22;156(14):1558-64.</citation>
    <PMID>8687264</PMID>
  </reference>
  <reference>
    <citation>Breitbart W, Rosenfeld B, Pessin H, Kaim M, Funesti-Esch J, Galietta M, Nelson CJ, Brescia R. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 2000 Dec 13;284(22):2907-11.</citation>
    <PMID>11147988</PMID>
  </reference>
  <reference>
    <citation>Haverkate I, Onwuteaka-Philipsen BD, van Der Heide A, Kostense PJ, van Der Wal G, van Der Maas PJ. Refused and granted requests for euthanasia and assisted suicide in the Netherlands: interview study with structured questionnaire. BMJ. 2000 Oct 7;321(7265):865-6.</citation>
    <PMID>11021864</PMID>
  </reference>
  <reference>
    <citation>Meier DE, Emmons CA, Litke A, Wallenstein S, Morrison RS. Characteristics of patients requesting and receiving physician-assisted death. Arch Intern Med. 2003 Jul 14;163(13):1537-42.</citation>
    <PMID>12860575</PMID>
  </reference>
  <reference>
    <citation>Buiting HM, Gevers JK, Rietjens JA, Onwuteaka-Philipsen BD, van der Maas PJ, van der Heide A, van Delden JJ. Dutch criteria of due care for physician-assisted dying in medical practice: a physician perspective. J Med Ethics. 2008 Sep;34(9):e12. doi: 10.1136/jme.2008.024976.</citation>
    <PMID>18757612</PMID>
  </reference>
  <reference>
    <citation>Rietjens JA, van der Maas PJ, Onwuteaka-Philipsen BD, van Delden JJ, van der Heide A. Two Decades of Research on Euthanasia from the Netherlands. What Have We Learnt and What Questions Remain? J Bioeth Inq. 2009 Sep;6(3):271-283. Epub 2009 Jul 28.</citation>
    <PMID>19718271</PMID>
  </reference>
  <reference>
    <citation>Emanuel LL. Facing requests for physician-assisted suicide: toward a practical and principled clinical skill set. JAMA. 1998 Aug 19;280(7):643-7.</citation>
    <PMID>9718058</PMID>
  </reference>
  <reference>
    <citation>Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011 Mar;47(5):702-12. doi: 10.1016/j.ejca.2010.11.027. Epub 2011 Jan 4. Review.</citation>
    <PMID>21211961</PMID>
  </reference>
  <reference>
    <citation>Rayner L, Price A, Evans A, Valsraj K, Hotopf M, Higginson IJ. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med. 2011 Jan;25(1):36-51. doi: 10.1177/0269216310380764. Epub 2010 Oct 8. Review.</citation>
    <PMID>20935027</PMID>
  </reference>
  <reference>
    <citation>Ujeyl M, Müller-Oerlinghausen B. [Antidepressants for treatment of depression in palliative patients : a systematic literature review]. Schmerz. 2012 Sep;26(5):523-36. doi: 10.1007/s00482-012-1221-x. Review. German.</citation>
    <PMID>22968366</PMID>
  </reference>
  <reference>
    <citation>Willner P, Scheel-Krüger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 1):2331-71. doi: 10.1016/j.neubiorev.2012.12.007. Epub 2012 Dec 19. Review.</citation>
    <PMID>23261405</PMID>
  </reference>
  <reference>
    <citation>Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013 Jun;19(6):370-80. doi: 10.1111/cns.12099. Epub 2013 Apr 10.</citation>
    <PMID>23575437</PMID>
  </reference>
  <reference>
    <citation>Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64.</citation>
    <PMID>16894061</PMID>
  </reference>
  <reference>
    <citation>Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010 Aug 20;329(5994):959-64. doi: 10.1126/science.1190287.</citation>
    <PMID>20724638</PMID>
  </reference>
  <reference>
    <citation>Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011 Apr 15;69(8):754-61. doi: 10.1016/j.biopsych.2010.12.015. Epub 2011 Feb 3.</citation>
    <PMID>21292242</PMID>
  </reference>
  <reference>
    <citation>Monteggia LM, Gideons E, Kavalali ET. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry. 2013 Jun 15;73(12):1199-203. doi: 10.1016/j.biopsych.2012.09.006. Epub 2012 Oct 11. Review.</citation>
    <PMID>23062356</PMID>
  </reference>
  <reference>
    <citation>Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011 Nov;16(11):1068-70. doi: 10.1038/mp.2011.47. Epub 2011 Apr 19.</citation>
    <PMID>21502951</PMID>
  </reference>
  <reference>
    <citation>Li X, Jope RS. Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology. 2010 Oct;35(11):2143-54. doi: 10.1038/npp.2010.105. Epub 2010 Jul 28. Review.</citation>
    <PMID>20668436</PMID>
  </reference>
  <reference>
    <citation>Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl). 2013 Nov;230(2):291-8. doi: 10.1007/s00213-013-3153-2. Epub 2013 Jun 4.</citation>
    <PMID>23732839</PMID>
  </reference>
  <reference>
    <citation>Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011 Jun 15;475(7354):91-5. doi: 10.1038/nature10130.</citation>
    <PMID>21677641</PMID>
  </reference>
  <reference>
    <citation>Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011 Oct 10;224(1):107-11. doi: 10.1016/j.bbr.2011.05.035. Epub 2011 Jun 6.</citation>
    <PMID>21669235</PMID>
  </reference>
  <reference>
    <citation>Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, Ritter MJ, Schak KM, Sola CL, Hanson AJ, Frye MA. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 2013 May;27(5):444-50. doi: 10.1177/0269881113478283. Epub 2013 Feb 20.</citation>
    <PMID>23428794</PMID>
  </reference>
  <reference>
    <citation>Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009 Sep 1;66(5):522-6. doi: 10.1016/j.biopsych.2009.04.029. Epub 2009 Jul 9.</citation>
    <PMID>19545857</PMID>
  </reference>
  <reference>
    <citation>Thakurta RG, Das R, Bhattacharya AK, Saha D, Sen S, Singh OP, Bisui B. Rapid response with ketamine on suicidal cognition in resistant depression. Indian J Psychol Med. 2012 Apr;34(2):170-5. doi: 10.4103/0253-7176.101793.</citation>
    <PMID>23162195</PMID>
  </reference>
  <reference>
    <citation>Glue P, Gulati A, Le Nedelec M, Duffull S. Dose- and exposure-response to ketamine in depression. Biol Psychiatry. 2011 Aug 15;70(4):e9-10; author reply e11-2. doi: 10.1016/j.biopsych.2010.11.031. Epub 2011 Apr 8.</citation>
    <PMID>21481846</PMID>
  </reference>
  <reference>
    <citation>Loo CK, Katalinic N, Garfield JB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J Affect Disord. 2012 Dec 15;142(1-3):233-40. doi: 10.1016/j.jad.2012.04.032. Epub 2012 Aug 2.</citation>
    <PMID>22858219</PMID>
  </reference>
  <reference>
    <citation>Thakurta RG, Ray P, Kanji D, Das R, Bisui B, Singh OP. Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression? Indian J Psychol Med. 2012 Jan;34(1):56-60. doi: 10.4103/0253-7176.96161.</citation>
    <PMID>22661809</PMID>
  </reference>
  <reference>
    <citation>Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27.</citation>
    <PMID>22840761</PMID>
  </reference>
  <reference>
    <citation>Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012 Aug;169(8):868-9. doi: 10.1176/appi.ajp.2012.12020219.</citation>
    <PMID>22854933</PMID>
  </reference>
  <reference>
    <citation>Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry. 2010 Jan;43(1):33-5. doi: 10.1055/s-0029-1237375. Epub 2009 Dec 11.</citation>
    <PMID>20013614</PMID>
  </reference>
  <reference>
    <citation>Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.</citation>
    <PMID>23982301</PMID>
  </reference>
  <reference>
    <citation>Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi: 10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7. Review.</citation>
    <PMID>25575710</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Palliative care</keyword>
  <keyword>Supportive care</keyword>
  <keyword>Early palliative care</keyword>
  <keyword>Fast acting antidepressant</keyword>
  <keyword>End of life care</keyword>
  <keyword>Cancer</keyword>
  <keyword>psychological distress</keyword>
  <keyword>antidepressant</keyword>
  <keyword>serotonin norepinephrine reuptake inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

